Oncology
Non-Small Cell Lung Cancer
Expert Roundtables Podcast: Targeted Therapies for Mutation-Driven Non–Small Cell Lung Cancer
Comprehensive biomarker testing is becoming increasingly important across metastatic and early-stage non–small cell lung cancer (NSCLC), yet disparities in access, tissue adequacy, and testing practices persist. Today’s podcast features a discussion with Charu Aggarwal, MD, MPH, FASCO, Narjust Florez, MD, FASCO, and Helena A. Yu, MD, on practical testing strategies and recent advances across EGFR-, HER2-, ALK-, RET-, ROS1-, and other mutation-driven NSCLC subsets.
Cho BC, Lu S, Felip E, et al; MARIPOSA Investigators. Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC. N Engl J Med. 2024;391(16):1486-1498. doi:10.1056/NEJMoa2403614
Evangelist M, Wang B, Butrynski JE, et al. Biomarker testing rates and patterns in patients with metastatic non–small cell lung cancer: a prospective, observational study in community practices. JCO Precis Oncol. 2026;10(4):e2500832. doi:10.1200/PO-25-00832
Jänne PA, Planchard D, Kobayashi K, et al; FLAURA2 Investigators. Survival with osimertinib plus chemotherapy in EGFR-mutated advanced NSCLC. N Engl J Med. 2026;394(1):27-38. doi:10.1056/NEJMoa2510308
Li W, Zhang Y, Fan H, et al. Long-term efficacy and safety of taletrectinib in patients with ROS1+ non–small cell lung cancer: results from the phase II TRUST-I study. J Clin Oncol. 2026;44(18):1670-1675. doi:10.1200/JCO-26-00434
Pérol M, Li W, Pennell NA, et al. Taletrectinib in ROS1+ non–small cell lung cancer: TRUST. J Clin Oncol. 2025;43(16):1920-1929. doi:10.1200/JCO-25-00275
Wu YL, Hochmair M, Yang Y, et al; LIBRETTO-432 Trial Investigators. Selpercatinib in early-stage RET fusion–positive non–small-cell lung cancer. N Engl J Med. 2026;395(7):660-670. doi:10.1056/NEJMoa2602628


